Dan Vogl, MD
University of Pennsylvania · Abramson Cancer Center · Abramson Cancer Center at Penn Medicine
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Dan Vogl, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:11 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT04405167 · Tasquinimod for the Treatment of Relapsed or Refractory MyelomaUniversity of Pennsylvania · terminated · Multiple Myeloma · principal investigator
- N/ANCT01985919 · Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood SamplesAbramson Cancer Center at Penn Medicine · completed · No Restrictions on Diagnosis · principal investigator
- Early Ph1NCT01594242 · Autophagy Induction After Bortezomib for MyelomaAbramson Cancer Center at Penn Medicine · completed · Multiple Myeloma · principal investigator
- Early Ph1NCT01396200 · Cyclophosphamide and Pulse Dexamethasone With Rapamycin or HydroxychloroquineAbramson Cancer Center at Penn Medicine · completed · Myeloma · principal investigator
- Ph1NCT00568880 · Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple MyelomaAbramson Cancer Center at Penn Medicine · completed · Multiple Myeloma and Plasma Cell Neoplasm · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:11 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in multiple myeloma.